New insights into the mechanism of low high-density lipoprotein cholesterol in obesity

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Wang, Hao ^a   Peng, Dao Quan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

adipocytes; HDL C; hepatocytes; microRNA 33; Obesity

Indexed keywords

ABC TRANSPORTER A1; ADIPOCYTOKINE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; TRIACYLGLYCEROL; ABC TRANSPORTER; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIRN33 MICRORNA, HUMAN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ADIPOCYTE; ADIPOSE TISSUE; CHOLESTEROL TRANSPORT; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER; OBESITY; REVIEW; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; LIVER CELL; METABOLISM; PATHOPHYSIOLOGY;

ADIPOCYTES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HEPATOCYTES; HUMANS; LIPOPROTEINS, HDL; MICRORNAS; OBESITY; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 80053926900     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-176     Document Type: Review

References (98)

1. Obesity. Haslam DW, James WP, Lancet 2005 366 9492 1197 1209 10.1016/S0140-6736(05)67483-1 16198769 (Pubitemid 41393598)
2. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH, Circulation 2006 113 6 898 918 10.1161/CIRCULATIONAHA.106.171016 16380542
3. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A, Sarwar N, Kizer JR, Lawlor DA, Nordestgaard BG, et al. Lancet 2011 377 9771 1085 1095 21397319
4. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, et al. N Engl J Med 1999 341 6 410 418 10.1056/ NEJM199908053410604 10438259 (Pubitemid 29362514)
5. High-density lipoprotein as a therapeutic target: a systematic review. Singh IM, Shishehbor MH, Ansell BJ, Jama 2007 298 7 786 798 10.1001/jama.298.7. 786 17699012 (Pubitemid 47263161)
6. Dysfunctional HDL as a diagnostic and therapeutic target. Smith JD, Arterioscler Thromb Vasc Biol 2009 30 2 151 155 19679832
7. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Shah PK, Kaul S, Nilsson J, Cercek B, Circulation 2001 104 19 2376 2383 10.1161/hc4401.098467 11696481 (Pubitemid 33049524)
8. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. Attie AD, Kastelein JP, Hayden MR, J Lipid Res 2001 42 11 1717 1726 11714841 (Pubitemid 33116703)
9. Understanding the mechanism of LCAT reaction may help to explain the high predictive value of LDL/HDL cholesterol ratio. Dobiasova M, Frohlich J, Physiol Res 1998 47 6 387 397 10453745 (Pubitemid 29089118)
10. Molecular regulation of macrophage reverse cholesterol transport. Wang X, Rader DJ, Curr Opin Cardiol 2007 22 4 368 372 10.1097/HCO.0b013e3281ec5113 17556891 (Pubitemid 46897290)
11. Hugh sinclair lecture: the regulation and remodelling of HDL by plasma factors. Barter PJ, Atheroscler Suppl 2002 3 4 39 47 10.1016/S1567-5688(02) 00041-7 12573362 (Pubitemid 38234485)
12. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. Ji Y, Wang N, Ramakrishnan R, Sehayek E, Huszar D, Breslow JL, Tall AR, J Biol Chem 1999 274 47 33398 33402 10.1074/jbc.274.47.33398 10559220 (Pubitemid 129511644)
13. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, et al. Circulation 2000 101 5 477 484 10662743 (Pubitemid 30080860)
14. Increasing HDL Cholesterol Levels. Brewer HB Jr, N Engl J Med 2004 350 15 1491 1494 10.1056/NEJMp048023 15071124 (Pubitemid 38477773)
15. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Ford ES, Giles WH, Dietz WH, Jama 2002 287 3 356 359 10.1001/jama.287.3.356 11790215 (Pubitemid 34251969)
16. Multiple risk factors for cardiovascular disease and diabetes mellitus. Smith SC Jr, Am J Med 2007 120 3 Suppl 1 3 S11 17720359
17. Plasma high-density lipoprotein cholesterol: association with measurements of body mass. The Lipid Research Clinics Program Prevalence Study. Glueck CJ, Taylor HL, Jacobs D, Morrison JA, Beaglehole R, Williams OD, Circulation 1980 62 4 Pt 2 IV-62-69
18. Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Lamon-Fava S, Wilson PW, Schaefer EJ, Arterioscler Thromb Vasc Biol 1996 16 12 1509 1515 10.1161/01.ATV.16.12.1509 8977456 (Pubitemid 26427605)
19. Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra-abdominal fat. Despres JP, Moorjani S, Ferland M, Tremblay A, Lupien PJ, Nadeau A, Pinault S, Theriault G, Bouchard C, Arteriosclerosis 1989 9 2 203 210 10.1161/01.ATV.9.2.203 2923576 (Pubitemid 19092103)
20. Ultrasonography measurement of intrabdominal visceral fat in obese men. Association with alterations in serum lipids and insulinemia. Navarro E, Mijac V, Ryder HF, Arch Latinoam Nutr 2010 60 2 160 167 21427883
21. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Nieves DJ, Cnop M, Retzlaff B, Walden CE, Brunzell JD, Knopp RH, Kahn SE, Diabetes 2003 52 1 172 179 10.2337/diabetes.52.1.172 12502509 (Pubitemid 36042123)
22. Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein. Smith JD, J Clin Lipidol 2010 4 5 382 388 10.1016/j.jacl.2010.08. 007 21076633
23. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M, J Clin Invest 1995 96 6 2758 2767 10.1172/JCI118345 8675645
24. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horvath T, Doerries C, Heinemann M, et al. Circulation 2010 121 1 110 122 10.1161/CIRCULATIONAHA.108.836346 20026785
25. Cholesterol transport between cells and high density lipoprotein subfractions from obese and lean subjects. Sasahara T, Nestel P, Fidge N, Sviridov D, J Lipid Res 1998 39 3 544 554 9548587 (Pubitemid 28158397)
26. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, et al. N Engl J Med 2011 364 2 127 135 10.1056/NEJMoa1001689 21226578
27. The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. Rashid S, Uffelman KD, Lewis GF, J Diabetes Complications 2002 16 1 24 28 10.1016/S1056-8727(01)00191-X 11872362 (Pubitemid 34168496)
28. Effect of obesity on high-density lipoprotein metabolism. Rashid S, Genest J, Obesity (Silver Spring) 2007 15 12 2875 2888 10.1038/oby.2007.342 (Pubitemid 351256646)
29. Obesity-related changes in high-density lipoprotein metabolism. Mooradian AD, Haas MJ, Wehmeier KR, Wong NC, Obesity (Silver Spring) 2008 16 6 1152 1160 10.1038/oby.2008.202 (Pubitemid 351770500)
30. Thematic review series: patient-oriented research. What have we learned about HDL metabolism from kinetics studies in humans? Rashid S, Patterson BW, Lewis GF, J Lipid Res 2006 47 8 1631 1642 10.1194/jlr.R600008-JLR200 16685079 (Pubitemid 44222815)
31. Insulin resistance and cardiovascular disease. Ginsberg HN, J Clin Invest 2000 106 4 453 458 10.1172/JCI10762 10953019 (Pubitemid 30666377)
32. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Dullaart RP, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A, Eur J Clin Invest 1994 24 3 188 194 10.1111/j.1365-2362.1994.tb00987.x 8033953 (Pubitemid 24197267)
33. The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. Carr MC, Hokanson JE, Zambon A, Deeb SS, Barrett PH, Purnell JQ, Brunzell JD, J Clin Endocrinol Metab 2001 86 6 2831 2837 10.1210/jc.86.6.2831 11397895 (Pubitemid 32545747)
34. Biochemical and physical properties of remnant-HDL2 and of pre beta 1-HDL produced by hepatic lipase. Guendouzi K, Jaspard B, Barbaras R, Motta C, Vieu C, Marcel Y, Chap H, Perret B, Collet X, Biochemistry 1999 38 9 2762 2768 10.1021/bi9815086 10052947 (Pubitemid 29122336)
35. Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. Xiao C, Watanabe T, Zhang Y, Trigatti B, Szeto L, Connelly PW, Marcovina S, Vaisar T, Heinecke JW, Lewis GF, Circ Res 2008 103 2 159 166 10.1161/CIRCRESAHA.108.178756 18556574
36. When HDL gets fat. Brown RJ, Rader DJ, Circ Res 2008 103 2 131 132 10.1161/CIRCRESAHA.108.180638 18635830
37. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. Badellino KO, Wolfe ML, Reilly MP, Rader DJ, PLoS Med 2006 3 2 22 10.1371/journal.pmed.0030022 16354105 (Pubitemid 43362878)
38. Altered properties of high density lipoprotein subfractions in obese subjects. Sasahara T, Yamashita T, Sviridov D, Fidge N, Nestel P, J Lipid Res 1997 38 3 600 611 9101441 (Pubitemid 27166703)
39. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR, N Engl J Med 1990 323 18 1234 1238 10.1056/NEJM199011013231803 2215607 (Pubitemid 20366528)
40. A review of CETP and its relation to atherosclerosis. de Grooth GJ, Klerkx AH, Stroes ES, Stalenhoef AF, Kastelein JJ, Kuivenhoven JA, J Lipid Res 2004 45 11 1967 1974 10.1194/jlr.R400007-JLR200 15342674 (Pubitemid 40990890)
41. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ, N Engl J Med 2004 350 15 1505 1515 10.1056/NEJMoa031766 15071125 (Pubitemid 38477775)
42. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N, Cell Metab 2008 7 5 365 375 10.1016/j.cmet.2008.03.001 18460328 (Pubitemid 351598023)
43. Safety of anacetrapib in patients with or at high risk for coronary heart disease. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, et al. N Engl J Med 2010 363 25 2406 2415 10.1056/NEJMoa1009744 21082868
44. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. Chan DC, Nguyen MN, Watts GF, Barrett PH, J Clin Endocrinol Metab 2008 93 2 557 564 10.1210/jc.2006-2676 18000086 (Pubitemid 351240831)
45. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Shachter NS, Curr Opin Lipidol 2001 12 3 297 304 10.1097/00041433-200106000-00009 11353333 (Pubitemid 32521955)
46. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L, J Lipid Res 2008 49 8 1746 1751 10.1194/jlr.M800102-JLR200 18421072
47. Overproduction of large VLDL particles is driven by increased liver fat content in man. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Hakkinen A, Olofsson SO, Yki-Jarvinen H, et al. Diabetologia 2006 49 4 755 765 10.1007/s00125-005-0125-z 16463046 (Pubitemid 43357551)
48. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S, Gastroenterology 2008 134 2 424 431 10.1053/j.gastro.2007.11.038 18242210 (Pubitemid 351173050)
49. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, et al. Nature 2007 447 7147 959 965 10.1038/nature05844 17554340 (Pubitemid 46975747)
50. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Goossens GH, Physiol Behav 2008 94 2 206 218 10.1016/j.physbeh.2007.10.010 18037457 (Pubitemid 351615418)
51. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. Haghpassand M, Bourassa PA, Francone OL, Aiello RJ, J Clin Invest 2001 108 9 1315 1320 11696576 (Pubitemid 33107759)
52. Adipose tissue and cholesterol metabolism. Krause BR, Hartman AD, J Lipid Res 1984 25 2 97 110 6368715 (Pubitemid 14150090)
53. Adipocyte cholesterol balance in obesity. Le Lay S, Ferre P, Dugail I, Biochem Soc Trans 2004 32 Pt 1 103 106 14748723 (Pubitemid 38283024)
54. Adipocyte modulation of high-density lipoprotein cholesterol. Zhang Y, McGillicuddy FC, Hinkle CC, O'Neill S, Glick JM, Rothblat GH, Reilly MP, Circulation 2010 121 11 1347 1355 10.1161/CIRCULATIONAHA.109.897330 20212278
55. Stimulation of lipolysis enhances the rate of cholesterol efflux to HDL in adipocytes. Verghese PB, Arrese EL, Soulages JL, Mol Cell Biochem 2007 302 1-2 241 248 10.1007/s11010-007-9447-0 17390217 (Pubitemid 47202340)
56. The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels. Williams PT, Metabolism 2004 53 6 700 709 10.1016/j.metabol.2004.01.004 15164315 (Pubitemid 38880898)
57. Influence of weight reduction on plasma lipoproteins in obese patients. Wolf RN, Grundy SM, Arteriosclerosis 1983 3 2 160 169 10.1161/01.ATV.3.2.160 6573161 (Pubitemid 13136502)
58. Human adipocyte cholesterol. Concentration, localization, synthesis, and turnover. Schreibman PH, Dell RB, J Clin Invest 1975 55 5 986 993 10.1172/JCI108028 1123433
59. A novel efflux-recapture process underlies the mechanism of high-density lipoprotein cholesteryl ester-selective uptake mediated by the low-density lipoprotein receptor-related protein. Vassiliou G, McPherson R, Arterioscler Thromb Vasc Biol 2004 24 9 1669 1675 10.1161/01.ATV.0000134295.09932.60 15178567 (Pubitemid 39180893)
60. Unique pathway for cholesterol uptake in fat cells. Fazio S, Linton MF, Arterioscler Thromb Vasc Biol 2004 24 9 1538 1539 10.1161/01.ATV.0000140821. 25572.1b 15345518 (Pubitemid 39180873)
61. In vivo evidence for a role of adipose tissue SR-BI in the nutritional and hormonal regulation of adiposity and cholesterol homeostasis. Yvan-Charvet L, Bobard A, Bossard P, Massiera F, Rousset X, Ailhaud G, Teboul M, Ferre P, Dagher G, Quignard-Boulange A, Arterioscler Thromb Vasc Biol 2007 27 6 1340 1345 10.1161/ATVBAHA.106.136382 17363694 (Pubitemid 46809423)
62. Characterization of high density lipoprotein binding to human adipocyte plasma membranes. Fong BS, Rodrigues PO, Salter AM, Yip BP, Despres JP, Angel A, Gregg RE, J Clin Invest 1985 75 6 1804 1812 10.1172/JCI111893 2989332 (Pubitemid 15237788)
63. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, et al. Circulation 2001 103 8 1057 1063 11222466 (Pubitemid 32200177)
64. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, et al. Biochem Biophys Res Commun 1999 257 1 79 83 10.1006/bbrc.1999.0255 10092513 (Pubitemid 29299050)
65. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. Baratta R, Amato S, Degano C, Farina MG, Patane G, Vigneri R, Frittitta L, J Clin Endocrinol Metab 2004 89 6 2665 2671 10.1210/jc.2003-031777 15181039 (Pubitemid 38766347)
66. Adiponectin as a biomarker of the metabolic syndrome. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T, Circ J 2004 68 11 975 981 10.1253/circj.68.975 15502375 (Pubitemid 39540124)
67. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, Okazaki Y, Ishii T, Nishikai K, Saruta T, Clin Sci (Lond) 2002 103 2 137 142 10.1042/CS20010336
68. Adiponectin is an important determinant of apoA-I catabolism. Verges B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F, Gambert P, Arterioscler Thromb Vasc Biol 2006 26 6 1364 1369 10.1161/01.ATV.0000219611.50066.bd 16574896 (Pubitemid 44305383)
69. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Matsuura F, Oku H, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Maeda N, Tsujii K, Ishigami M, et al. Biochem Biophys Res Commun 2007 358 4 1091 1095 10.1016/j.bbrc.2007. 05.040 17521614 (Pubitemid 46829000)
70. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. Oku H, Matsuura F, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Maeda N, Ohama T, Ishigami M, et al. FEBS Lett 2007 581 26 5029 5033 10.1016/j.febslet.2007.09.038 17936760 (Pubitemid 47576080)
71. High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. Neumeier M, Sigruener A, Eggenhofer E, Weigert J, Weiss TS, Schaeffler A, Schlitt HJ, Aslanidis C, Piso P, Langmann T, et al. Biochem Biophys Res Commun 2007 352 2 543 548 10.1016/j.bbrc.2006.11.058 17129575 (Pubitemid 44838520)
72. Lipid profiles in untreated patients with rheumatoid arthritis. Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, Song CH, Lee J, J Rheumatol 1999 26 8 1701 1704 10451065 (Pubitemid 29367308)
73. Month-to-month variability of lipids, lipoproteins, and apolipoproteins and the impact of acute infection in adolescents. Gidding SS, Stone NJ, Bookstein LC, Laskarzewski PM, Stein EA, J Pediatr 1998 133 2 242 246 10.1016/S0022-3476(98)70227-6 9709713 (Pubitemid 28385202)
74. Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta. Haas MJ, Horani M, Mreyoud A, Plummer B, Wong NC, Mooradian AD, Biochim Biophys Acta 2003 1623 2-3 120 128 14572909 (Pubitemid 37315668)
75. Inhibition of apolipoprotein AI gene expression by tumor necrosis factor alpha: roles for MEK/ERK and JNK signaling. Beers A, Haas MJ, Wong NC, Mooradian AD, Biochemistry 2006 45 7 2408 2413 10.1021/bi0518040 16475830 (Pubitemid 43271341)
76. Inflammation impairs reverse cholesterol transport in vivo. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP, Circulation 2009 119 8 1135 1145 10.1161/CIRCULATIONAHA. 108.810721 19221221
77. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR, J Lipid Res 2003 44 9 1728 1736 10.1194/jlr.M300100-JLR200 12777468 (Pubitemid 37185884)
78. Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. Wellington CL, Brunham LR, Zhou S, Singaraja RR, Visscher H, Gelfer A, Ross C, James E, Liu G, Huber MT, et al. J Lipid Res 2003 44 8 1470 1480 10.1194/jlr.M300110-JLR200 12730295 (Pubitemid 37279591)
79. Clinical significance of high-density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter. Brewer HB Jr, Santamarina-Fojo S, Am J Cardiol 2003 92 4B 10K 16K 12948871
80. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, et al. J Clin Invest 2005 115 5 1333 1342 15841208 (Pubitemid 40629053)
81. On the hepatic mechanism of HDL assembly by the ABCA1/apoA-I pathway. Tsujita M, Wu CA, Abe-Dohmae S, Usui S, Okazaki M, Yokoyama S, J Lipid Res 2005 46 1 154 162 15520446 (Pubitemid 40066681)
82. Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. Singaraja RR, Van Eck M, Bissada N, Zimetti F, Collins HL, Hildebrand RB, Hayden A, Brunham LR, Kang MH, Fruchart JC, et al. Circulation 2006 114 12 1301 1309 10.1161/CIRCULATIONAHA.106.621433 16940190 (Pubitemid 44402056)
83. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, et al. J Clin Invest 2006 116 4 1052 1062 10.1172/JCI27352 16543947
84. MiR-33 contributes to the regulation of cholesterol homeostasis. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, Fernandez-Hernando C, Science 2010 328 5985 1570 1573 10.1126/science.1189862 20466885
85. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM, Science 2010 328 5985 1566 1569 10.1126/science.1189123 20466882
86. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, Kinoshita M, Kuwabara Y, Marusawa H, Iwanaga Y, et al. Proc Natl Acad Sci USA 2010 107 40 17321 17326 10.1073/pnas.1008499107 20855588
87. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, et al. J Clin Invest 2011
88. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, Leclercq IA, Macdougald OA, Bommer GT, J Biol Chem 2010
89. MicroRNAs in lipid metabolism. Fernandez-Hernando C, Suarez Y, Rayner KJ, Moore KJ, Curr Opin Lipidol 2011 22 2 86 92 10.1097/MOL.0b013e3283428d9d 21178770
90. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. Horton JD, Goldstein JL, Brown MS, J Clin Invest 2002 109 9 1125 1131 11994399 (Pubitemid 34496588)
91. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Chen G, Liang G, Ou J, Goldstein JL, Brown MS, Proc Natl Acad Sci USA 2004 101 31 11245 11250 10.1073/pnas.0404297101 15266058 (Pubitemid 39038332)
92. Insulin activates the rat sterol-regulatory-element-binding protein 1c (SREBP-1c) promoter through the combinatorial actions of SREBP, LXR, Sp-1 and NF-Y cis-acting elements. Cagen LM, Deng X, Wilcox HG, Park EA, Raghow R, Elam MB, Biochem J 2005 385 Pt 1 207 216 15330762
93. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Endo M, Masaki T, Seike M, Yoshimatsu H, Exp Biol Med (Maywood) 2007 232 5 614 621 (Pubitemid 46683386)
94. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. Awazawa M, Ueki K, Inabe K, Yamauchi T, Kaneko K, Okazaki Y, Bardeesy N, Ohnishi S, Nagai R, Kadowaki T, Biochem Biophys Res Commun 2009 382 1 51 56 10.1016/j.bbrc.2009.02.131 19254698
95. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Pettinelli P, Del Pozo T, Araya J, Rodrigo R, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Korn O, et al. Biochim Biophys Acta 2009 1792 11 1080 1086 19733654
96. Dysregulation of sterol regulatory element binding protein-1c in livers of morbidly obese women is associated with altered suppressor of cytokine signaling-3 and signal transducer and activator of transcription-1 signaling. Elam MB, Yellaturu C, Howell GE, Deng X, Cowan GS, Kumar P, Park EA, Hiler ML, Wilcox HG, Hughes TA, et al. Metabolism 2009 59 4 587 598 19913854
97. Increased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat. Elam MB, Wilcox HG, Cagen LM, Deng X, Raghow R, Kumar P, Heimberg M, Russell JC, J Lipid Res 2001 42 12 2039 2048 11734577 (Pubitemid 34001053)
98. Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (Apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice. Hayek T, Ito Y, Azrolan N, Verdery RB, Aalto-Setala K, Walsh A, Breslow JL, J Clin Invest 1993 91 4 1665 1671 10.1172/JCI116375 8473509 (Pubitemid 23127371)